Preclinical toxicity biomarkers for combination treatment with clotting factors rFXIII and rFVIIa.
Combination treatment with the clotting factors recombinant activated factor VII (rFVIIa), serine protease, and recombinant factor XIII (rFXIII), protransglutaminase, is being explored for haemostatic therapy. We performed a single-dose toxicology study in the cynomolgus monkey, with four dose groups receiving 0.1 + 0.34 mg kg(-1) (group 1), 0.33 + 1.12 mg kg(-1) (group 2), 1.67 + 5.60 mg kg(-1) (group 3) and 5.00 + 16.80 mg kg(-1) (group 4) of a rFVIIa + rFXIII combination. In the three lower dose groups, no clinical, histopathological or blood chemistry changes were observed. In group 4, the animals died at 4 h post-dosing, with histopathology revealing a systemic coagulopathy resembling, but distinct from, disseminated intravascular coagulation. Due to the absence of toxicity warning signs, toxicity biomarkers were identified by a Western blot-based screening of approximately 20 plasma proteins known to be involved in the clotting cascade. Three of the examined proteins were specifically affected by rFVIIa + rFXIII treatment. Fibronectin and fibrinogen exhibited dose-dependent reductions from less than 10% reduction (group 2) to more than 90% reduction (group 4). These reductions were reversible, and specific. For vitronectin, a dose-dependent conversion to the 65-kDa form was found to occur in groups 3 and 4. Thus, fibrinogen, fibronectin and vitronectin represent the first biomarkers for clotting factor toxicity.
Oleksiewicz
M B
MB
Novo Nordisk A/S, Maalov, Denmark. mboz@novonordisk.com
Schaal-Jensen
R
R
Kiehr
B
B
Krabbe
J Steenbuch
JS
Sommer
C
C
D000818:Animals; D015415:Biomarkers / Q000097:blood*; D015153:Blotting, Western; D004353:Drug Evaluation, Preclinical; D015942:Factor VIIa / Q000633:toxicity*; D005176:Factor XIII / Q000633:toxicity*; D005340:Fibrinogen / Q000032:analysis*; D005353:Fibronectins / Q000097:blood*; D006489:Hemostatic Techniques / Q000009:adverse effects; D006801:Humans; D008252:Macaca fascicularis; D011994:Recombinant Proteins / Q000633:toxicity; D019096:Vitronectin / Q000097:blood*
D015415:Biomarkers; D005353:Fibronectins; D011994:Recombinant Proteins; D019096:Vitronectin; D005340:Fibrinogen; D005176:Factor XIII; D015942:Factor VIIa